There’s a lot to be optimistic about in the Healthcare sector as 1 analysts just weighed in on and Allogene Therapeutics (ALLO) with bullish sentiments.
Allogene Therapeutics (ALLO)
B.Riley Financial analyst Kalpit Patel reiterated a Buy rating on Allogene Therapeutics on May 20 and set a price target of $52.00. The company’s shares closed last Tuesday at $25.37, close to its 52-week low of $24.56.
According to TipRanks.com, Patel is ranked #4989 out of 7540 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Allogene Therapeutics with a $49.38 average price target, representing a 92.7% upside. In a report issued on May 5, William Blair also reiterated a Buy rating on the stock.
See today’s analyst top recommended stocks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
